Prime Medicine Bio (PRME) Long-Term Debt to Capital Ratio
Prime Medicine, Inc. (PRME) is currently in the primary research stage, meaning its budget relies on external investments rather than sales. The absence of political risks and support from Western corporations provide a stable environment for development. The asset value potential is high due to the precision genome editing method, which is confirmed by this price chart, where the indicator stands at 2.79.
Comprehensive metric breakdowns and analytics for Prime Medicine, Inc. (PRME)
- current price and projected stock value:
- market capitalization details:
- issuer book value statistics:
- debt and solvency information:
All Debt to Shareholders' Equity Ratio Prime Medicine, Inc.|PRME - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient primemedicine.com|PRME - Company Debts|Debt to Book Value Prime Medicine, Inc.|PRME - Company Long-Term Debts|Short-Term Debt Prime Medicine|Intermediate Coverage Ratio primemedicine.com
- net income and valuation ratios data:
Comprehensive company analysis:PRME Prime Medicine Inc
Prime Medicine, Inc. (PRME) requires colossal R&D expenditures to maintain its status as a pioneer in precision genome editing, making the analysis of long-term debt-to-equity ratios critically important. This ratio correlates obligations exceeding one year with equity, allowing for an assessment of the funding stability for innovations against the tightening of the Fed's monetary policy and refinancing risks in the absence of current operating profit.
Key competitors
Long-Term Debt to Capital Ratio TEM (Tempus)|Long-Term Debt to Equity Qiagen Group (QGEN)|Isis Pharmaceuticals - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital RGEN (Repligen Corporation)|Long-Term Debt to Capital aviditybiosciences.com RNA|CRSP - Long-Term Debt to Equity|Long-Term Liabilities to Equity WGS|Ultragenyx Pharma (RARE) - Long-Term Debt to Equity|Beam Tx - Long-Term Debt to Capital Coefficient|SRPT (Sarepta Therapeutics, Inc.) - Long-Term Debt to Capital|twistbioscience.com (TWST) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity 10x Genomics (TXG)|Long-Term Debt to Equity Ratio Intellia Therapeutics Inc NTLA|Long-Term Debt to Capital STOK (Stoke)|BioLife (BLFS) - Long-Term Liabilities to Capital|WVE: Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient MAZE (mazetx.com)|Sionna Therapeutics (SION) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Taysha Gene Therapies Inc|QURE (uniQure Corp) - Long-Term Debt to Capital|Long-Term Liabilities to Capital MeiraGTx Corp MGTX|Long-Term Debt to Capital RGNX|solidbio.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Capital OCGN (Ocugen)|Ratio of Long-Term Indebtedness to Capital Pacific Biosciences of California, Inc. (PACB)|Benitec - Long-Term Debt to Capital|Design Corp (DSGN) - Long-Term Debt to Equity Ratio|RCKT: Long-Term Debt to Capital|FDMT - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Lexeo Therapeutics Inc.|Long-Term Debt to Capital Ratio KRRO (Korro Bio, Inc)|Long-Term Debt to Capital EDIT|SLN - Long-Term Liabilities to Capital|ProQR Therapeutics - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient CDXS|Sangamo Therapeutics, Inc. - Long-Term Debt to Capital|Ratio of Long-Term Indebtedness to Capital Nautilus Biotechnology NAUT|Metagenomi, Inc (MGX) - Long-Term Debt to Equity|Long-Term Debt to Capital Ratio DTIL|GBIO (Generation Bio Co) - Long-Term Debt to Capital|Long-Term Debt to Equity Ratio boundlessbio.com (BOLD)|Long-Term Debt to Equity Ratio XCUR (Exicure, Inc.)|Ratio of Long-Term Indebtedness to Capital imunon.com|Long-Term Debt to Equity Phio Pharmaceuticals Corp. PHIO|MBIO (Mustang Bio Inc) - Long-Term Liabilities to Equity|RNAZ - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient BNGO (Bionano Genomics, Inc.)|Applied DNA Sciences, Inc. (APDN) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio bluebird bio Inc.|IPA (ImmunoPrecise Antibodies Ltd) - Long-Term Debt to Capital|Long-Term Liabilities to Capital Omega Therapeutics Corp OMGA|Long-Term Debt to Capital OMIC|regulusrx.com - Long-Term Debt to Capital Ratio|Long-Term Debt to Equity Syros Pharmaceuticals, Inc. SYRS|TBIO: Long-Term Debt to Capital Ratio|TRACON - Long-Term Debt to Capital|UBX - Long-Term Debt to Capital